C3 and skin infection: Furthermore, the stable immune and blood biochemical profile of non-human primates (NHP) subjected to prolonged, systemic C3 inhibition, together with the faster skin wound healing and absence of skin infections in NHPs treated with the C3 inhibitor Cp40, further attest to the safety of this targeting approach (151).